Inhibition of de novo ceramide synthesis by sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes
Cardiovascular Research · 2024
DOI: 10.1093/cvr/cvae100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Srividya Velagapudi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland. Hauptthemen laut MEDLINE: Blood Glucose, Ceramides, Diabetes Mellitus, Type 2, Insulin Resistance. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Swiss National Research Foundation, Swiss Heart Foundation, Theodor-Ida-Herzog-Egli Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Obesity and type 2 diabetes (T2D) are major risk factors for cardiovascular (CV) diseases. Dysregulated pro-apoptotic ceramide synthesis reduces β-cell insulin secretion, thereby promoting hyperglycaemic states that may manifest as T2D. Pro-apoptotic ceramides modulate insulin sensitivity and glucose tolerance while being linked to poor CV outcomes. Sirtuin-1 (SIRT1) is a NAD + -dependent deacetylase that protects against pancreatic β-cell dysfunction; however, systemic levels are decreased in obese–T2D mice and may promote pro-apoptotic ceramide synthesis and hyperglycaemia. Herein, we aimed to assess the effects of restoring circulating SIRT1 levels to prevent metabolic imbalance in obese and diabetic mice. Methods and results Circulating SIRT1 levels were reduced in obese–diabetic mice (db/db) as compared to age-matched non-diabetic db/+ controls. Restoration of SIRT1 plasma levels with recombinant murine SIRT1 for 4 weeks prevented body weight gain and improved glucose tolerance, insulin sensitivity, and vascular function in mice models of obesity and T2D. Untargeted lipidomics revealed that SIRT1 restored insulin secretory function of β-cells by reducing synthesis and accumulation of pro-apoptotic ceramides. Molecular mechanisms involved direct binding to and deacetylation of Toll-like receptor 4 (TLR4) by SIRT1 in β-cells, thereby decreasing the rate-limiting enzymes of sphingolipid synthesis SPTLC1/2 via AKT/NF-κB. Among patients with T2D, those with high baseline plasma levels of SIRT1 prior to metabolic surgery displayed restored β-cell function (HOMA2-β) and were more likely to have T2D remission during follow-up.
Conclusion
Acetylation of TLR4 promotes β-cell dysfunction via ceramide synthesis in T2D, which is blunted by systemic SIRT1 replenishment. Hence, restoration of systemic SIRT1 may provide a novel therapeutic strategy to counteract toxic ceramide synthesis and mitigate CV complications of T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
- Institute of Clinical Chemistry, University Hospital Zürich, Zürich, Switzerland.
- Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
- Department of Cardiology, Center for Translational and Experimental Cardiology (CTEC), Zurich University Hospital and University of Zürich, Zürich, Switzerland.
- Department of Internal Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, Genoa, Italy.
- IRCCS Ospedale Policlinico San Martino Genoa-Italian Cardiovascular Network, Genoa, Italy.
ORCID-Profile: Srividya Velagapudi, Fabrizio Montecucco, Federico Carbone, Hyun-Duk Jang, Simon Kraler, Hyo-Soo Kim, Thorsten Hornemann, Alexander Akhmedov, Thomas F Lüscher
Förderung
- Swiss National Research Foundation
- Swiss Heart Foundation
- Theodor-Ida-Herzog-Egli Foundation
- Foundation for Cardiovascular Research-Zurich Heart House
- Center for Molecular Cardiology
- Lindenhofstiftung
- National Research Foundation of Korea
- Theiler-Haag
Zitieren
APA
Velagapudi, S., Karsai, G., Karsai, M., Mohammed, S. A., Montecucco, F., Liberale, L., Lee, H., Carbone, F., Adami, G. F., Yang, K., Crucet, M., Stein, S., Paneni, F., Lapikova-Bryhinska, T., Jang, H. D., Kraler, S., Vdovenko, D., Züllig, R. A., Camici, G. G., …, & Lüscher, T. F. (2024). Inhibition of de novo ceramide synthesis by sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae100
Vancouver
Velagapudi S, Karsai G, Karsai M, Mohammed SA, Montecucco F, Liberale L, et al. Inhibition of de novo ceramide synthesis by sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae100
BibTeX
@article{Velagapudi2024,
author = {Velagapudi, Srividya and Karsai, Gergely and Karsai, Maria and Mohammed, Shafeeq A and Montecucco, Fabrizio and Liberale, Luca and Lee, Hwan and Carbone, Federico and Adami, Giovanni Francesco and Yang, Kangmin and Crucet, Margot and Stein, Sokrates and Paneni, Franceso and Lapikova-Bryhinska, Tetiana and Jang, Hyun-Duk and Kraler, Simon and Vdovenko, Daria and Züllig, Richard Arnold and Camici, Giovanni G and Kim, Hyo-Soo and Laaksonen, Reijo and Gerber, Philipp A and Hornemann, Thorsten and Akhmedov, Alexander and Lüscher, Thomas F},
title = {Inhibition of de novo ceramide synthesis by sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes},
journal = {Cardiovascular Research},
year = {2024},
doi = {10.1093/cvr/cvae100}
}
EUVIMED